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We are at an exciting juncture in the treatment of haemophilia. The 
first gene therapy product for patients with haemophilia could re-
ceive regulatory approval as soon as August 2020, with several other 
products close on the horizon. Gene therapy carries the potential 
for a ‘functional cure of haemophilia’, with bleeding essentially elim-
inated in the majority of treated patients for the duration of multi-
year follow-up reports to date.1-3 This is a dream that has been in the 
making since the cloning of the F8 and F9 genes in the early 1980s.4-9
Although the potential for these transformative gene therapies 
is huge, emerging technologies by definition have some unknowns in 
their safety and efficacy profiles.10 Such novel therapies are usually 
evaluated and approved based on a small number of treated individ-
uals. Most phase I-II gene therapy clinical trials in haemophilia enroll 
less than 30 patients and current phase III trial protocols plan for 
enrolment of 40-134 patients.11 For a long lasting, potentially life 
long, therapy, mandated follow-up by the FDA is only 5 years, a rel-
atively short time.12 This imposes a heavy reliance on the postmar-
keting surveillance to gather critical post-therapy evidence of safety 
and durable efficacy.10
Some data will come from open-label extensions of ongoing 
phase III and future phase IV clinical trials; however, much of the 
burden will be on registry studies to amass long-term data on a large 
cohort of patients. While clinical trial data provide reassurance of 
short-term safety and efficacy of specific gene therapy products, we 
are entering this new treatment era with limited experience of the 
longer-term impact of gene therapy. Ultimately, the accumulation of 
patient exposure captured in longitudinal registries is the most ro-
bust means of revealing unexpected or rare events associated with 
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this new technology class. Detecting low incident or delayed safety 
events, particularly in small treatment cohorts of a rare disease, ne-
cessitates that each patient who receives gene therapy be followed 
over the long term, preferably their lifetime.
Our current knowledge leaves many unanswered questions about 
the safety and long-term efficacy of gene therapy.10,13-16 These gaps 
in evidence dictate that we must all contribute to strengthening the 
evidence base. This data collection/surveillance effort should be a 
shared responsibility. Healthcare providers and patients will need to 
work together to collect standardized data on patients who receive 
gene therapy, ensuring that their experiences are captured in a reg-
istry, over their entire lifetime. Such longer-term data will assist reg-
ulators and manufacturers who are also closely monitoring signals of 
potential safety events and may provide assistance to payers regard-
ing the efficacy and potential safety milestones needed to inform 
their reimbursement strategies.
Surveillance in rare diseases such as haemophilia necessitates a 
global reach, as patients who receive gene therapy will be dispersed 
throughout many countries and continents.17 A global strategy is 
required to ensure a large enough patient pool to allow robust eval-
uation and detection of low-incident events that may otherwise go 
undetected. If events are captured in disparate registries or data-
bases, it would be more complex, laborious, technically challenging 
and ultimately slower to combine the data. Such delays should be 
avoided at all cost. As the overall field of gene therapy continues to 
make progress, a growing set of long-term safety and efficacy data 
will ultimately define the future of gene therapy in haemophilia.
Integrating the collection of data into the clinical practice of phy-
sicians and the daily lives of patients requires a harmonious and uni-
form data collection methodology that will be accepted and used by 
all stakeholders. Only through cohesive efforts by all treating phy-
sicians, patients, regulatory agencies and manufacturers worldwide, 
will we be successful in ensuring gene therapy is safe and efficacious 
for our patients today, and in the future.
Through a collaboration with the International Society of 
Thrombosis and Hemostasis (ISTH), the European Haemophilia 
Consortium (EHC), the US National Hemophilia Foundation (NHF), 
the American Thrombosis and Hemostasis Network (ATHN), industry 
gene therapy development partners and Regulatory liaisons, the WFH 
has formulated a world Gene Therapy Registry (WFH GTR), that aims 
to collect a standardized set of core data, developed with input from 
a multi-stakeholder steering committee. The aim of the WFH GTR 
project is to provide a robust, scientifically valid data collection ave-
nue, available to all healthcare providers treating patients who receive 
gene therapy. The WFH GTR will collaborate with individual haemo-
philia treatment centres and existing gene therapy registries to lever-
age established data repositories. A patient mobile application will 
allow integrating patient-reported outcomes directly into the WFH 
GTR. The data stemming from the WFH GTR will provide for robust 
ongoing surveillance of safety and efficacy.8 We are now expanding 
our outreach for the WFH GTR to the provider and patient communi-
ties with implementation of the registry to begin later in 2020.
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